Roche and Novartis Strengthen Their Presence in the MS Market

Roche and Novartis Strengthen Their Presence in the MS Market

Source: 
BioSpace
snippet: 
Genentech, a Roche company, released data from a long-term clinical trial of Ocrevus in multiple sclerosis. Meanwhile, Novartis isn’t standing still on MS. Earlier this week the company announced that both the FDA and EMA had accepted its NDA and MAA, respectively, for siponimod.